PE is the third leading cause of vascular mortality, after myocardial infarction and stroke. It is an enormously heterogeneous and unpredictable disease, which makes treatment difficult. As such, it should not be surprising that PE therapy remains highly controversial. For example, the new European Society of Cardiology guidelines recommend anticoagulation and watchful waiting for high-risk submassive PE (with salvage thrombolysis as needed). Meanwhile, in the United States, PE response teams (PERT teams) are typically employing more aggressive approaches to these same high-risk submassive PE patients. The use of systemic thrombolysis, interventional radiology strategies, and ECMO remain highly variable across different countries and different centers. Additional research is needed to resolve these controversies.
The IBCC chapter is located here.
- The podcast & comments are below (the podcast is our longest yet at ~90 minutes of PE insanity! It's taking a little while, but will be out soon.)
Follow us on iTunes
The Podcast Episode
Want to Download the Episode?
Right Click Here and Choose Save-As
Latest posts by Josh Farkas (see all)
- PulmCrit-The Rothman Index:Artificial intelligence or merely a symptom of a broken healthcare system? - January 25, 2020
- IBCC chapter & cast – Toxic Alcohols - January 23, 2020
- PulmCrit – An alternative view of the PEPTIC trial - January 22, 2020